tiprankstipranks

Penumbra price target raised to $270 from $232 at BTIG

BTIG raised the firm’s price target on Penumbra (PEN) to $270 from $232 and keeps a Buy rating on the shares. The MedTech tape has been up 3.2% since earnings season kicked off on October 15, the analyst tells investors in a research note. Following the U.S. election, BTIG believes devices, an area that generally gets bipartisan support, should be in a stronger relative position within the healthcare landscape under various scenarios.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue